In this video, Motley Fool health-care analyst David Williamson discusses some phase 3 trial results for Celgene's (CELG +0.00%) pipeline drug Apremilast in the treatment of psoriasis. Investor excitement over the drug had been raised to a fever pitch, so when the drug failed to hit the same high marks it had reached in phase 2, there was some disappointment. However, in the video, David tells investors everything that the drug still has going for it, and why it may have a leg up on the competition in this space.
Celgene Trial Disappointment No Disaster
By Dave Williamson – Mar 4, 2013 at 6:02PM
NASDAQ: CELG
Celgene
Trial results for Celgene's new drug weren't as good as hoped, but they aren't catastrophic.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid